CSL’s earnings jump as blood plasma products boom

Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period.

Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion.

CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result for the 2024 financial year was driven by CSL Behring’s exceptional performance across its portfolio, especially immunoglobulins.

“The plasma initiatives we have implemented are starting to drive gross margin recovery.”

Sales of immunoglobulins, which are a vital component of the immune response to infection, were up 23 percent on the previous corresponding period to $2.76 billion driven by available plasma supply and patient demand.

CSL’s HIZENTRA human liquid subcutaneous immunoglobulin were up 18 percent, haemophilia products were up eight percent and sales of albumin were up eight percent to $613 million.

Dr McKenzie said: “CSL Seqirus achieved solid growth in a challenging season – its portfolio of differentiated products outperformed the market.”

Total revenue for CSL Seqirus, the world’s number 2 in vaccines, was $1.8 billion up two percent.

CSL’s recently acquired Vifor healthcare business reported revenue of $1.01 billion.

In 2021 CSL paid $17.2 billion cash for Swiss pharmaceutical manufacturer Vifor taking the company into complementary business areas including haematology, thrombosis, cardiovascular and transport treatments.

Further reading:
Browse @AuManufacturing’s coverage of CSL here.
Biotech giant CSL in massive global takeover

Picture: CSL/plasma manufacturing